Analysts have raised the price target for Adaptimmune Therapeutics from $0.64 to $0.98 per share. This change reflects increased optimism on future revenue growth and profit margins, despite a slightly higher discount rate.
What's in the News
- Adaptimmune Therapeutics plc has been dropped from the Nasdaq Composite Index (Key Developments)
- On September 22, 2025, the company received an exception period from the Nasdaq Hearings Panel to regain compliance with the $1.00 minimum bid price requirement. The deadline to meet this rule and avoid delisting is December 1, 2025 (Key Developments)
- On September 11, 2025, Adaptimmune received notice from Nasdaq for not meeting the $35 million minimum market value of listed securities. The company has until March 10, 2026 to regain compliance or face delisting (Key Developments)
- The company has also been removed from the S&P Global BMI Index (Key Developments)
- In August 2025, Nasdaq notified the company of continued non-compliance with minimum bid price rules and scheduled a hearing. Trading will continue while a decision is pending (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has increased from $0.64 to $0.98 per share, representing a substantial upward revision.
- The Discount Rate has risen slightly from 12.77% to 13.28%.
- Revenue Growth is now projected at 44.8%, compared to the previous estimate of 40.8%.
- Net Profit Margin shows a small increment, moving from 16.25% to 16.40%.
- Future P/E Ratio has increased from 9.1x to 12.9x, reflecting updated earnings expectations.
Have other thoughts on Adaptimmune Therapeutics?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.